Search Results

Arranta Bio announced the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta.

Study will evaluate Nephure vs. placebo in the reduction of urinary oxalate associated with food

Arranta Bio, the leading microbiome contract development and manufacturing organization, announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility.

Arranta Bio, the leading microbiome contract development and manufacturing organization, announced the addition of a 130,000-square-foot facility in Boxborough, Massachusetts, to complement its existing facilities in Watertown, Massachusetts and Gainesville, Florida, bringing the total manufacturing capacity at Arranta to over 230,000 square feet.

Arranta Bio, the leading microbiome contract development and manufacturing organization, announced the addition of Shailesh Maingi to Arranta’s board as an Independent Director.

Arranta Bio announced the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development.

Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process development laboratory expansion project and a commitment to add additional early-clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical

The company is commercializing its FDA-cleared bio-ConneKt® Wound Matrix to the advance wound care market.